Massari, FrancescoCiccarese, ChiaraSantoni, MatteoLopez-Beltran, AntonioScarpelli, MarinaMontironi, RodolfoCheng, Liang2016-05-262016-05-262015Massari, F., Ciccarese, C., Santoni, M., Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Cheng, L. (2015). Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 15(12), 1367–1369. http://doi.org/10.1586/14737140.2015.1110488https://hdl.handle.net/1805/9679Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.enPublisher Policyfibroblast growth factor receptorkidneypersonalized medicineArticle